Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia.

ABSTRACT:

Purpose

Infection with oncogenic human papillomaviruses has been linked to the development of cervical neoplasia and cancer. The exclusive expression of E7, a viral oncogene, in infected cells makes this protein an ideal target for immunotherapy. We recently reported on the results of a trial in women with cervical carcinoma-in-situ using HspE7, a protein vaccine consisting of full length HPV16 E7 linked to a heat shock protein from M. bovis. The stimulating effects of HspE7 on specific cytotoxic T lymphocytes have been demonstrated in vitro and in (pre-)clinical trials. The induction of a B-cell response by HspE7 and its association with clinical outcome is unknown, and is the purpose of this study.

Experimental design

We measured the serum IgG levels against HPV16 E7 and H

SUBMITTER: Van Doorslaer K 

PROVIDER: S-EPMC2813920 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature